RxDoctor Payments Data

Amy Main

Psychiatric/Mental Health · Winston Salem, NCNPI 1205301710

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,606 of the $6,255 with a category attached, or 89.6%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,571 and has fallen 68.1% since, to $821 in 2025. Among psychiatric/mental health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,255in general payments, 2019–2025

Across 264 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Johnson & Johnson$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$861
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$617
  • Otsuka America Pharmaceutical, Inc.$448
  • plus $848 from 7 others

What the payments were for

  • Travel & lodging$3205%
  • Food & beverage$5,60690%
  • Education$3285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,255 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$128,725
Invega SustennaPaliperidone Palmitate32$113,236
VraylarCariprazine Hcl37$57,870
LybalviOlanzapine/Samidorphan Malate17$26,276
FanaptIloperidone12$21,535
Lurasidone Hcl34$15,324
Aripiprazole56$7,509
TrintellixVortioxetine Hydrobromide12$6,010
Haloperidol Decanoate32$3,159
Quetiapine Fumarate ErQuetiapine Fumarate53$2,753
Paliperidone ErPaliperidone34$2,569
Divalproex Sodium ErDivalproex Sodium45$1,905
Ziprasidone Hcl18$1,477
Ramelteon12$1,247
Trazodone Hcl94$893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$363$128,72518 claims
Johnson & JohnsonInvega Sustenna$1,051$113,23632 claims
AbbVieVraylar$861$57,87037 claims
Alkermes, Inc.Lybalvi$1,382$26,27617 claims
Vanda Pharmaceuticals Inc.Fanapt$148$21,53512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →